Chemomab Therapeutics (CMMB) vs Senti Biosciences (SNTI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Chemomab Therapeutics (CMMB) has outperformed Senti Biosciences (SNTI) over the past year, losing 60.3% versus a loss of 81.9%. Over five years, CMMB leads with a -96.2% price change compared with -99.7% for SNTI. Chemomab Therapeutics is the larger company by market cap ($10.2 million vs $10.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CMMB | SNTI |
|---|---|---|
| Share price | $1.39 | $0.3217 |
| Market cap | $10.19M | $10.02M |
| 1-day change | +2.21% | -2.52% |
| YTD return | -15.76% | -69.07% |
| 1-year return | -60.29% | -81.93% |
| 5-year return | -96.18% | -99.68% |
| EPS (TTM) | $-1.04 | $-1.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.55 | $2.88 |
| 52-week low | $1.05 | $0.29 |
| Distance from 52-week high | -60.85% | -88.83% |
| Analyst consensus | none | none |
| Avg. price target upside | +259.71% | +4096.46% |
| Average volume | 118.53K | 573.78K |
| Shares outstanding | 7.33M | 31.15M |
| Employees | — | 39 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CMMB has outperformed SNTI by 21.6 percentage points over the past year.
About Chemomab Therapeutics
CMMB stock →Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis.
Healthcare · Biotechnology
About Senti Biosciences
SNTI stock →Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need.
Healthcare · Biotechnology · 39 employees
CMMB vs SNTI FAQ
Which is bigger, Chemomab Therapeutics or Senti Biosciences?
Chemomab Therapeutics (CMMB) is larger, with a market capitalization of $10.19M compared with $10.02M for Senti Biosciences (SNTI).
Which stock has performed better over the past year, CMMB or SNTI?
CMMB returned -60.29% over the past 12 months, compared with -81.93% for SNTI (price return, excluding dividends). Past performance does not predict future results.
Are Chemomab Therapeutics and Senti Biosciences in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.